非小细胞肺癌免疫治疗最新进展与挑战  

Advances and challenges in immunotherapy for non- small cell lung cancer

作　　者：程森森 马原[1,2] 宋宝[3] 刘杰[1] 

机构地区：[1]山东省肿瘤医院内三科,济南市250117 [2]山东省医学科学院济南大学医学与生命科学学院 [3]山东省肿瘤医院基础实验室

出　　处：《中国肿瘤临床》2015年第20期1031-1036,共6页Chinese Journal of Clinical Oncology

摘　　要：肺癌在中国乃至全球范围内是威胁人类健康最常见的恶性肿瘤之一,发病率和死亡率居高不下,预后也较差。近年来,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)虽然在手术治疗、化疗、放疗及靶向治疗方面均取得了很大进展,但其疗效并不令人满意,晚期NSCLC患者的5年生存率仍然很低。随着肿瘤免疫学及分子生物学的发展,肺癌的免疫治疗得到广泛关注,并为非小细胞肺癌患者提供了新的治疗方向。免疫治疗种类繁多,有免疫检测点受体抑制剂、主动性免疫疫苗和过继性免疫疫苗等。I期临床试验显示了较高缓解率,Ⅱ期/Ⅲ期临床试验亦在进一步探索中。本文就当前非小细胞肺癌免疫治疗的最新进展及面临的挑战进行概述。Lung cancer is the leading cause of cancer-related deaths, with high morbidity and mortality, as well as poor prognosis in China and worldwide. Despite the recent advances in surgery, irradiation, chemotherapy, and targeted therapy, the curative effect of non-small cell lung cancer （NSCLC） in advanced cancer patients is unsatisfactory, and the five-year survival rate of patients remains low. Immunotherapeutic approaches, such as checkpoint inhibitors, active vaccination, and adoptive vaccination, have been given in-creasing attention for the treatment of patients with NSCLC. Results of phase I clinical trials show a higher remission rate, and the out-comes of phases II and III clinical trials are under exploration. This review provides an overview of the latest advances and challenges in immunotherapy for NSCLC.

关 键 词：肺非小细胞肺癌 免疫治疗 肿瘤疫苗 检测点阻滞剂 进展 

分 类 号：R734.2[医药卫生—肿瘤]